CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$57.12
+0.95%Oct 5, 2026, 12:00 UTC
Celcuity Inc. announced that a late-breaking rapid oral presentation and three poster presentations on its gedatolisib clinical trial data will be featured at the ESMO Congress 2026, to be held October 23-27, 2026, in Madrid, Spain.
Source:Oct 2, 2026, 12:07 UTC
Celcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.
Sep 30, 2026, 12:00 UTC
Celcuity Inc. announced that REVTORPYK (gedatolisib) is now commercially available in the United States for eligible patients with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation after progression on at least one line of endocrine therapy.
Source:Aug 26, 2026, 12:30 UTC
Celcuity Inc. submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for REVTORPYK (gedatolisib) to treat HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer.
Source:Aug 25, 2026, 07:55 UTC
Brandywine Managers LLC acquired a new stake in Celcuity, Inc. (NASDAQ: CELC) during the second quarter, purchasing 6,621 shares valued at approximately $693,000, as disclosed in a recent SEC filing.
Source:Aug 14, 2026, 13:11 UTC
Celcuity Inc. launched REVTORPYK (gedatolisib) commercially following FDA approval and NCCN Category 1 inclusion.
Source:Aug 13, 2026, 20:06 UTC
Celcuity Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Jul 23, 2026, 01:47 UTC
Celcuity received FDA approval for its breast cancer therapy Revtorpyk.
Source:Jul 15, 2026, 20:17 UTC
Celcuity Inc. announced commercial launch plans for REVTORPYK following FDA approval.
Jul 15, 2026, 12:43 UTC
Celcuity delays the commercial launch of its newly approved breast cancer drug.
Source:Jul 14, 2026, 20:53 UTC
The U.S. Food and Drug Administration approved Celcuity's REVTORPYK (gedatolisib) for the treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer.
Jun 8, 2026, 00:00 UTC
Celcuity Inc. issued $575 million aggregate principal amount of 0.250% Convertible Senior Notes due 2032 in an underwritten public offering, with net proceeds of approximately $557.0 million to repay outstanding obligations under its prior loan agreement and for working capital and general corporate purposes.
Jun 4, 2026, 02:13 UTC
Celcuity Inc. priced an upsized public offering of $500 million aggregate principal amount of 0.250% convertible senior notes due 2032.